Protecting the Gut Microbiome

Synthetic Biologics is developing cutting-edge therapeutics to treat pathogen-specific diseases. 

Our two leading candidates are:
SYN-004 (ribaxamase) to prevent C. difficile infection and antibiotic-associated diarrhea
SYN-010 to treat irritable bowel syndrome with constipation (IBS-C)

View SYN-004 (ribaxamase) View SYN-010

About Synthetic Biologics

We are a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients.

Learn More

Leadership

Our experienced management team has an extensive clinical and commercial track record.

Latest News

Apr 26, 2017 • 4:05pm EDT

Synthetic Biologics to Report First Quarter 2017 Operational Highlights and Financial Results on May 4, 2017

-- Conference Call Scheduled for Thursday, May 4, 2017 at 4:30 p.m. EDT -- ROCKVILLE, Md., April, 26, 2017 /PRNewswire/ --

View all news

Investor Relations

Symbol NYSE MKT: SYN
Price
Change
Volume
Day Low/High
52 Week Low/High